Contributing Author
in
Bioeconomy & Society
Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.
Just in time for 2025 prediction season, a survey of the emerging AI drug discovery landscape, prepared by Chris Bradbury, has been making the rounds—and with good reason. The survey is likely the most comprehensive public review to date of advancements in this rapidly evolving field. AI drug discovery is categorized into four distinct waves of development, providing a clear framework for understanding how this technology has progressed. The most recent wave, in particular, emphasizes two key trends: (1) leveraging more data and extracting more value from diverse data sources through multimodal, multiscale, synthetic, and self-supervised approaches; and (2) focusing on more specialized pipelines, where feedback from the development process may be used more effectively.
